



**Theratechnologies Announces New Findings with the Investigational Antiretroviral Ibalizumab and with EGRIFTA® (tesamorelin for injection)**

July 24, 2017

Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced today that results on HIV susceptibility to ibalizumab from the Phase IIb trial, TMB-202, along with new findings for EGRIFTA® (tesamorelin for injection), are being presented during poster sessions at the 9 th IAS Conference on HIV Science (IAS 2017) in Paris, France.